{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 5 March 2007\line \line {\b Roche 
raises dividend by 36 percent} \line \line Annual General Meeting approves Annual 
Report and financial statements for 2006 and appoints Pius Baschera and Wolfgang Ruttenstorfer to Board 
of Directors\line \line Roche's Annual General Meeting, which was held today in 
Basel, has approved all the Board of Directors' proposals. The 680 shareholders in attendance, representing 
137,557,426 or 85.97% of a total of 160,000,000 bearer shares, approved the 2006 Annual Report and financial 
statements. They also authorised a 36% increase in the gross dividend to 3.40 Swiss francs per share 
and non-voting equity, the twentieth dividend increase in as many years. Pius Baschera, Chairman of 
the Board of Directors of Hilti Corporation, and Wolfgang Ruttenstorfer, Chief Executive Officer and 
Chairman of the Executive Board of the leading central European oil and gas Group OMV, were appointed 
to the Board of Directors.\line \line In his address to shareholders, Chairman and 
CEO Franz B. Humer summed up the year as follows: "We have maintained the strong business trend 
of recent years and achieved another extraordinarily good result - indeed the best in our company's 
110-year history. Roche's sustained business success and scientific achievements put us in the advantageous 
position, compared to many of our competitors, of being able to address the challenges and opportunities 
of the healthcare market from a position of strength."\line \line Dr Humer 
also commented on controversial issues. Speaking about remuneration for the Corporate Executive Committee 
and Board of Directors , he said that Roche had first published open and transparent figures on the 
subject in its 2002 Annual Report. "This year's Annual Report contains a separate chapter that 
provides a detailed and comprehensive breakdown of the amounts paid to all members of the Board and 
Executive Committee. The information disclosed in this chapter goes beyond the new requirements of the 
Code of Obligations. Executive Committee and top management remuneration at Roche is geared to clearly 
defined performance criteria."\line \line In his speech Arthur D. Levinson, 
Ph.D., Genentech's chairman and chief executive officer, underlined the unique relationship between 
Roche and Genentech. He pointed out that Roche and Genentech have a true collaboration across different 
areas including R&D and manufacturing, where the strengths of both companies are maximized. "Since 
Genentech's founding more than 30 years ago, science and innovation have been the driving force, and 
an important area of differentiation, behind our efforts to help patients with serious medical diseases" 
commented Arthur D. Levinson further. "Building on this commitment, in 2006 alone, Genentech received 
eight FDA approvals. During the past year, we focused on building our product portfolio, a key to our 
growth, adding seven new molecular entities to the development pipeline and receiving positive data 
from four Phase II clinical trials in oncology and immunology. In 2007 and beyond, we plan to continue 
to create value through excellent science, planning and investing for the long term, disciplined execution 
against our goals, and a passionate commitment to patients and our employees." \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the global leader 
in biotechnology, Roche contributes on a broad range of fronts to improving people\u8217?s health and quality 
of life by supplying innovative products and services for the early detection, prevention, diagnosis 
and treatment of diseases. Roche is the world leader in diagnostics, the leading supplier of drugs for 
cancer and transplantation and a market leader in virology. It is also engaged in other important therapeutic 
areas including autoimmune, inflammatory and metabolic disease and diseases of the central nervous system. 
In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics 
Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people worldwide and 
has R&D agreements and strategic alliances with numerous partners, including majority ownership 
interests in Genentech and Chugai. Additional information about the Roche Group is available on the 
Internet at www.roche.com.\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All trademarks used or mentioned 
in this release are protected by law.\par}\line \line {\b Further 
information} \line - Annual Report 2006\line - Roche 
Board of Directors \line \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}